Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 3563

1.

Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab.

Gonzalez-Buendia L, Delgado-Tirado S, Sanabria MR, Fernandez I, Coco RM.

BMC Ophthalmol. 2017 Aug 18;17(1):147. doi: 10.1186/s12886-017-0544-x.

PMID:
28821236
2.

ULTRASONOGRAPHIC FINDINGS IN THE VITREOUS OF PATIENTS WITH AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS.

Mato-Gondelle T, Bande MF, Paniagua L, Rodríguez-Cid MJ, Abraldes M, Fernández M, Blanco-Teijeiro MJ, Piñeiro A.

Retina. 2017 Aug 16. doi: 10.1097/IAE.0000000000001819. [Epub ahead of print]

PMID:
28820850
3.

RANIBIZUMAB AND AFLIBERCEPT FOR THE TREATMENT OF PIGMENT EPITHELIAL DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Data from an Observational Study.

Vaze A, Nguyen V, Daien V, Arnold JJ, Young SH, Cheung CM, Lamoureux E, Bhargava M, Barthelmes D, Gillies MC; Fight Retinal Blindness Study Group.

Retina. 2017 Aug 16. doi: 10.1097/IAE.0000000000001815. [Epub ahead of print]

PMID:
28820848
4.

Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience.

Bansal A, Bhende M, Sharma T, Bhende P, Mukherjee S.

Indian J Ophthalmol. 2017 Aug;65(8):758-760. doi: 10.4103/ijo.IJO_1003_16.

PMID:
28820169
5.

Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy.

Kang EC, Choi S, Koh HJ.

Graefes Arch Clin Exp Ophthalmol. 2017 Aug 17. doi: 10.1007/s00417-017-3776-9. [Epub ahead of print]

PMID:
28819823
6.

Systemic Associations with Residual Subretinal Fluid after Ranibizumab in Diabetic Macular Edema.

Tsai MJ, Hsieh YT, Shen EP, Peng YJ.

J Ophthalmol. 2017;2017:4834201. doi: 10.1155/2017/4834201. Epub 2017 Jul 27.

PMID:
28819567
7.

Early onset coats' disease initially treated as unilateral ROP at 39 weeks postmenstrual age: a case report.

Peng J, Zhang Q, Chen C, Huang Q, Li Y, Zhao P.

BMC Ophthalmol. 2017 Aug 16;17(1):145. doi: 10.1186/s12886-017-0536-x.

PMID:
28814287
8.

Real-Life Management of Patients with Retinal Vein Occlusion Using I-Macula Web Platform.

Nicolò M, Bonetto M, Rosa R, Musetti D, Musolino M, Traverso CE, Giacomini M.

J Ophthalmol. 2017;2017:5601786. doi: 10.1155/2017/5601786. Epub 2017 Jul 24.

9.

Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study.

Tadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E, Das Gupta A, Wenzel A, Pearce I; BRIGHTER Study Group.

Ophthalmology. 2017 Aug 11. pii: S0161-6420(17)30701-7. doi: 10.1016/j.ophtha.2017.06.027. [Epub ahead of print]

PMID:
28807635
10.

Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.

Daien V, Nguyen V, Essex RW, Morlet N, Barthelmes D, Gillies MC; Fight Retinal Blindness! Study Group.

Ophthalmology. 2017 Aug 8. pii: S0161-6420(17)30747-9. doi: 10.1016/j.ophtha.2017.07.005. [Epub ahead of print]

PMID:
28801117
11.

Protective effects on the retina after ranibizumab treatment in an ischemia model.

Joachim SC, Renner M, Reinhard J, Theiss C, May C, Lohmann S, Reinehr S, Stute G, Faissner A, Marcus K, Dick HB.

PLoS One. 2017 Aug 11;12(8):e0182407. doi: 10.1371/journal.pone.0182407. eCollection 2017.

12.

Dynamics of Inflammatory Factors in Aqueous Humor during Ranibizumab or Aflibercept Treatment for Age-Related Macular Degeneration.

Motohashi R, Noma H, Yasuda K, Kotake O, Goto H, Shimura M.

Ophthalmic Res. 2017 Aug 11. doi: 10.1159/000478705. [Epub ahead of print]

PMID:
28796997
13.

Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age.

Karagiannis D, Kontadakis GA, Kaprinis K, Giarmoukakis A, Georgalas I, Parikakis EA, Tsilimbaris MK.

Clin Ophthalmol. 2017 Jun 22;11:1197-1201. doi: 10.2147/OPTH.S135174. eCollection 2017.

14.

An Analysis of Medicare Reimbursement to Ophthalmologists: Years 2012 to 2013.

Han E, Baisiwala S, Jain A, Bundorf MK, Pershing S.

Am J Ophthalmol. 2017 Aug 4. pii: S0002-9394(17)30323-9. doi: 10.1016/j.ajo.2017.07.022. [Epub ahead of print]

PMID:
28784553
15.

Multifocal electroretinography changes at the 1-year follow-up in a cohort of diabetic macular edema patients treated with ranibizumab.

Baget-Bernaldiz M, Romero-Aroca P, Bautista-Perez A, Mercado J.

Doc Ophthalmol. 2017 Aug 4. doi: 10.1007/s10633-017-9601-2. [Epub ahead of print]

PMID:
28779336
16.

Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial.

Wykoff CC, Ou WC, Croft DE, Payne JF, Brown DM, Clark WL, Abdelfattah NS, Sadda SR; TREX-AMD Study Group.

Br J Ophthalmol. 2017 Aug 4. pii: bjophthalmol-2017-310822. doi: 10.1136/bjophthalmol-2017-310822. [Epub ahead of print]

PMID:
28779006
17.

Choroidal neovascularization in multifocal choroiditis after dabrafenib and trametinib.

Albertini GC, Corbelli E, Battaglia Parodi M, Bandello F.

Eur J Ophthalmol. 2017 Aug 2:0. doi: 10.5301/ejo.5001013. [Epub ahead of print]

PMID:
28777388
18.

Bilateral choroidal neovascular membrane in a young patient with Sorsby fundus dystrophy: the value of prompt treatment.

Menassa N, Burgula S, Empeslidis T, Tsaousis KT.

BMJ Case Rep. 2017 Aug 3;2017. pii: bcr-2017-220488. doi: 10.1136/bcr-2017-220488.

PMID:
28775088
20.

IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.

Wirth MA, Wons J, Freiberg FJ, Becker MD, Michels S.

Retina. 2017 Aug 1. doi: 10.1097/IAE.0000000000001788. [Epub ahead of print]

PMID:
28767550

Supplemental Content

Loading ...
Support Center